BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29393100)

  • 1. Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts.
    Nagase H; Nakagawa F; Uchida J
    Chemotherapy; 2018; 63(1):46-52. PubMed ID: 29393100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
    Nukatsuka M; Saito H; Sakamoto K; Nakagawa F; Uchida J; Kobunai T; Shiraishi K; Takechi T
    Anticancer Res; 2012 Jul; 32(7):2807-12. PubMed ID: 22753741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice.
    Louvet C; Coudray AM; Tournigand C; Prévost S; Raymond E; de Gramont A; Chazard M; Gespach C
    Anticancer Drugs; 2000 Aug; 11(7):579-82. PubMed ID: 11036962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin.
    Jiang J; Zheng X; Xu X; Zhou Q; Yan H; Zhang X; Lu B; Wu C; Ju J
    PLoS One; 2011; 6(8):e23271. PubMed ID: 21876743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
    Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.
    Inadomi K; Kusaba H; Matsushita Y; Tanaka R; Mitsugi K; Arimizu K; Hirano G; Makiyama A; Ohmura H; Uchino K; Hanamura F; Shibata Y; Kuwayama M; Esaki T; Takayoshi K; Arita S; Ariyama H; Akashi K; Baba E
    Anticancer Res; 2017 May; 37(5):2663-2671. PubMed ID: 28476842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
    Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma.
    Gao SG; Jia RN; Feng XS; Xie XH; Shan TY; Pan LX; Song NS; Wang YF; Ding KL; Wang LD
    World J Gastroenterol; 2011 Dec; 17(47):5221-6. PubMed ID: 22215948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation by l-leucovorin of 1-hexylcarbamoyl-5-fluorouracil antitumor activity on human gastric and colon carcinomas serially transplanted into nude mice.
    Kubota T; Kase S; Furukawa T; Tanino H; Kuo TH; Saikawa Y; Nishibori H; Ishibiki K; Kitajima M; Mabuchi K
    Anticancer Res; 1992; 12(5):1549-53. PubMed ID: 1444220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical analysis of the antitumor efficacy of TS-1 using human uterine cervical cancer tumor xenografts.
    Nagai N; Komatsu M; Yunokawa M; Shiroyama Y; Hirata E
    Oncol Rep; 2008 Nov; 20(5):1149-56. PubMed ID: 18949415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
    Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
    Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models.
    Katoh R; Ooshiro M
    Cell Mol Immunol; 2007 Aug; 4(4):295-9. PubMed ID: 17764620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
    Wang ZQ; Zhang DS; Xu N; Luo DY; Deng YH; Wang FH; Luo HY; Qiu MZ; Li YH; Xu RH
    Chin J Cancer; 2016 Jan; 35():8. PubMed ID: 26739998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.
    Takahashi M; Hasegawa K; Oba M; Saiura A; Arita J; Sakamoto Y; Shinozaki E; Mizunuma N; Matsuyama Y; Kokudo N
    Invest New Drugs; 2016 Aug; 34(4):468-73. PubMed ID: 27155613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
    Qiu M; Peng XC; Bi F; Wang X; Li Q; Xu F; Li ZP; Shen YL; Liu JY; Zhao YQ; Cao D; Gou HF; Yang Y; Chen Y; Yi C
    Med Oncol; 2015 Jul; 32(7):191. PubMed ID: 26025485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.